Results 231 to 240 of about 6,262,928 (308)

Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Fragile X‐associated Tremor/Ataxia Syndrome (FXTAS) is the most severe late‐onset condition caused by a premutation in the FMR1 gene, characterized by expanded CGG triplet repeats of 55–200. Clinical presentations of FXTAS, including gait ataxia, kinetic tremor, cognitive decline, and rare Parkinsonism, are linked to ...
Flora Tassone, Freddy Chafota, Miguel E. Rentería, Randi J. Hagerman, Ellery Santos, Anna Atkinson, Nicholas G. Martin, Elsdon Storey, Danuta Z. Loesch   +8 more
wiley   +1 more source

ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases: An OECD Best Practice for Integrated Care for Chronic Diseases. [PDF]

Clin Transl Allergy
Bousquet J, Sousa-Pinto B, Shamji MH, Torres MJ, Klimek L, Schünemann HJ, Morais-Almeida M, Vieira RJ, Togias A, Samolinski B, Valiulis A, Williams S, Pfaar O, Zuberbier T, Bedbrook A, Czarlewski W, Al-Nesf MA, Amaral R, Anto JM, Bognanni A, Brussino L, Cruz AA, Kvedariene V, Douagui H, Papadopoulos NG, Canonica GW, Cherrez-Ojeda I, Dykewicz M, Gemicioglu B, Giovannini M, Gradauskiene B, Haahtela T, Jacomelli C, Jartti T, Jeseňák M, Kuna P, Larenas-Linnemann DE, Latiff AHA, Martin B, Mohammad Y, Nadeau K, Nunes E, Ohta K, Ouédraogo M, Mahesh PA, Pali-Schölll I, Pereira AM, Regateiro FS, Roche N, Sofiev M, Taborda-Barata L, Ulrik CS, Toppila-Salmi SK, Rostan MV, Vecillas LL, Ventura MT, Viegi G, Wang Y, Zhang H, Zhang L, Ciprandi G, Ivancevich JC, Khaltaev N, Lourenço O, Leemann L, Savouré M, Yepes-Nuñez JJ, Yorgancioglu A, Abdullah B, Al-Ahmad M, Asllani J, Bergmann KC, Bernstein JA, Blaiss MS, Braido F, Carreiro-Martins P, Cecchi L, Giuliano AFM, Christoff G, Cirule I, Correia-de-Sousa J, Costa EM, Cvetkovski B, Giacco SD, Devillier P, Dokic D, Gotua M, Guzman MA, Hossny E, Iinuma T, Irani C, Ispayeva Z, Julge K, Kaidashev I, Bennoor KS, Kraxner H, Kull I, Kulus M, Kupczyk M, Kurchenko A, Luo X, La Grutta S, Tuyet LLT, Makris M, Milenkovic B, Miculinic N, Lee SM, Montefort S, Moreira A, Mullol J, Nadif R, Nakonechna A, Neffen HE, Nicola S, Niedoszytko M, Nyembue D, O'Hehir RE, Ogulur I, Okamoto Y, Ollert M, Olze H, Palomares O, Panzner P, Park HS, Patella V, Pawankar R, Pitsios C, Popov TA, Puggioni F, Quirce S, Ramonaité A, Recto M, Repka-Ramirez MS, Robles-Velasco K, Rottem M, Salapatas M, Sastre J, Scichilone N, Sisul JC, Solé D, Soto-Martinez M, Sova M, Stevanovic K, Tantilipikorn P, Todo-Bom A, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Valovirta E, Vasankari T, Wallace D, Worm M, Yusuf OM, Zaitoun F, Zidarn M, ARIA study group.   +155 more
europepmc   +1 more source

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon, Dana Olofson, Diana Anissian, Divyanshu Dubey, Eoin P. Flanagan, Max C. Herman, Sarosh R. Irani, Daniel H. Lachance, Maria A. Willrich, Sean Pittock, John R. Mills, Anastasia Zekeridou   +11 more
wiley   +1 more source

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak, Marije M. C. Voermans, Hans Heijst, Charlotte E. Teunissen, Marc Engelen   +4 more
wiley   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk. [PDF]

Front Cell Dev Biol
Willems RAL, Zanetto A, Campello E, Konings J, Bulato C, Kramer M, Russo FP, Roest M, Senzolo M, Burra P, Cate HT, de Vos-Geelen J, de Laat B, Simioni P, de Laat-Kremers R.   +14 more
europepmc   +1 more source

Comparing the Effect of Semi‐Immersive Virtual Reality, Computerized Cognitive Training, and Traditional Rehabilitation on Cognitive Function in Multiple Sclerosis: A Randomized Clinical Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio, Desiree Latella, Lilla Bonanno, Paulo Cezar Rocha dos Santos, Marcos Maldonado‐Díaz, Meir Plotnik, Rosaria De Luca, Angelo Quartarone, Rocco Salvatore Calabrò   +8 more
wiley   +1 more source

Fatigue and Driving Safety in Early Parenthood: Developing Feasible Risk-Reduction Strategies Through Co-Design. [PDF]

Health Promot J Austr
Sprajcer M, Kovac K, Thomas MJW, Ferguson SA, Gupta CC, Bachmann A, Miller DJ, Thorne H, Bishop BC, Vincent GE.   +9 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source